
Immuno-Oncology
Latest Content

Latest Videos

Shorts
Podcasts
More News

The combination therapy met the primary OS end point vs durvalumab alone as first-line ES-SCLC maintenance therapy in the phase 3 DeLLphi-305 trial.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

Durvalumab plus BCG also marks the first new treatment in more than 30 years for high-risk non–muscle-invasive bladder cancer.

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

Hope Krebill, MSW, BSN, RN, discusses the challenges rural hospitals face in delivering therapies like CAR T and bispecifics.

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers, such as circulating tumor DNA and KRAS mutations, in guiding treatment decisions.

Although rare, clinicians should be familiar with the symptoms and management of immune checkpoint inhibitor (ICI)–related cardiovascular adverse effects or myocarditis.











